Equities

Legend Biotech Corp

Legend Biotech Corp

Actions
  • Price (USD)39.75
  • Today's Change-0.39 / -0.97%
  • Shares traded1.76m
  • 1 Year change-30.57%
  • Beta0.0822
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy7
Outperform16
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 22 analysts offering 12 month price targets for Legend Biotech Corp (ADR) have a median target of 84.50, with a high estimate of 95.00 and a low estimate of 60.00. The median estimate represents a 112.58% increase from the last price of 39.75.
High139.0%95.00
Med112.6%84.50
Low50.9%60.00

Earnings history & estimates in USD

On Nov 12, 2024, Legend Biotech Corp (ADR) reported 3rd quarter 2024 losses of -0.68 per share.
The next earnings announcement is expected on Mar 10, 2025.
Average growth rate-146.64%
Legend Biotech Corp (ADR) reported annual 2023 losses of -2.94 per share on Mar 11, 2024.
Average growth rate-38.80%
More ▼

Revenue history & estimates in USD

Legend Biotech Corporation had 3rd quarter 2024 revenues of 160.21m. This bettered the 143.87m consensus of the 14 analysts covering the company. This was 340.90% above the prior year's 3rd quarter results.
Average growth rate+21.35%
Legend Biotech Corporation had revenues for the full year 2023 of 285.14m. This was 143.70% above the prior year's results.
Average growth rate+64.22%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.